Goodkin, D E <br/><br/>
Ethical considerations raised by the approval of interferon beta-1b for the treatment of multiple sclerosis.  [electronic resource] 

 -  Neurology  Jan 1994 
 - 166-70 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0028-3878 
<br/><br/><label>Standard No.: </label>10.1212/wnl.44.1.166  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Bioethics<br/>Disclosure<br/>Drug Approval<br/>Ethical Analysis<br/>Federal Government<br/>Government Regulation<br/>Guidelines as Topic<br/>Humans<br/>Interferon-beta--therapeutic use<br/>Multicenter Studies as Topic<br/>Multiple Sclerosis--drug therapy<br/>Randomized Controlled Trials as Topic<br/>Research Subjects<br/>Risk Assessment<br/>Therapeutic Human Experimentation<br/>United States<br/>Withholding Treatment